This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jelle de Vries, MD; Saskia A. van de Merwe, MD; L. Jan de Heer, MD
Rotterdam, the Netherlands

Arch Ophthalmol. 1989;107(5):634.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In the July 1988 issue of the ARCHIVES, Lynch et al¹ reported on 18 patients with central nervous system (CNS) effects during timolol maleate therapy whose condition improved after switching to betaxolol hydrochloride therapy. Unfortunately, however, they did not report on the intraocular pressure.

Since betaxolol became available in the Netherlands in September 1986, we have prescribed this new antiglaucoma drug to 40 consecutive patients in whom timolol therapy was discontinued because of adverse effects. The group consisted of 27 women and 13 men, with an age range of 44 to 85 years (mean ± SD, 69.5 ± 9.2 years). Follow-up

ranged from three to 21 months (10.75 ± 5.0 months). We excluded all patients in whom the alleged side effects did not disappear after stopping both timolol and betaxolol therapies and made no changes in the concomitant ocular or systemic medication. Although several patients were . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?